Merck & Co Inc
MRK82.810USD
Today
-2.72%
5 Days
-2.24%
1 Month
+0.06%
6 Months
-12.44%
Year to Date
-16.76%
1 Year
-28.53%
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
Score Analysis
Analyst Rating
Company Highlights
News
Merck to Acquire Verona Pharma for $10 Billion in Bid to Cushion "Patent Cliff" Impact
TradingKey - U.S. pharmaceutical giant Merck (MRK.US) has announced a roughly $10 billion deal to acquire U.K.-based biopharma firm Verona Pharma (VRNA.US), marking a major move into the respiratory disease treatment space.
200% Drug Tariff Ultimatum by Trump: Are Patients the Victims of Tariffs?
TradingKey - During a Cabinet meeting at the White House on July 8, Trump announced plans to impose tariffs of up to 200% on imported drugs, requiring pharmaceutical companies to relocate their production chains to the United States and granting them a 1 to 1.5-year adjustment period. If companies..
Merck to Acquire Verona for $10 Billion — A Major Move into Respiratory Care, Shares of VRNA Surge 20%
TradingKey - According to a report by the Financial Times, U.S. pharmaceutical giant Merck (MRK.US) is nearing a deal to acquire Verona Pharma (VRNA.US) for $10 billion, marking Merck’s largest biopharma acquisition since 2023. The acquisition will expand Merck’s presence in the respiratory disease
Trump executive order demands pharma industry price cuts
WASHINGTON, May 12 (Reuters) - U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement.
Merck & Co Inc reports results for the quarter ended December 31 - Earnings Summary
Merck & Co Inc MRK.N reported quarterly adjusted earnings of $1.72 per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 3 cents. The mean expectation of sixteen analysts for the quarter was for earnings of $1.62 per share. Wall ...
U.S. STOCKS ON THE MOVE-Merck & Co, Sirius XM Holdings, Palantir Technologies
Eikon search string for individual stock moves: The Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refini.tv/3dKUyB8U.S. stock index futures were slightly lower on Tuesday as investors stayed away from risky assets after China deployed retaliatory tariffs...
Financial Indicators
EPS
Total revenue
Company
Related Instruments
